Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Enterprise Value (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Enterprise Value for 14 consecutive years, with -$172.1 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 36.62% to -$172.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$172.1 million through Dec 2025, down 36.62% year-over-year, with the annual reading at -$172.1 million for FY2025, 36.62% down from the prior year.
  • Enterprise Value hit -$172.1 million in Q4 2025 for Coherus Oncology, up from -$191.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$72.9 million in Q2 2023 to a low of -$468.7 million in Q3 2021.
  • Historically, Enterprise Value has averaged -$229.8 million across 5 years, with a median of -$191.7 million in 2022.
  • Biggest five-year swings in Enterprise Value: surged 73.53% in 2023 and later tumbled 118.35% in 2024.
  • Year by year, Enterprise Value stood at -$417.2 million in 2021, then skyrocketed by 54.05% to -$191.7 million in 2022, then soared by 38.57% to -$117.7 million in 2023, then dropped by 7.0% to -$126.0 million in 2024, then plummeted by 36.62% to -$172.1 million in 2025.
  • Business Quant data shows Enterprise Value for CHRS at -$172.1 million in Q4 2025, -$191.7 million in Q3 2025, and -$237.6 million in Q2 2025.